Paeonol
Catalog No: CFN98926
Paeonol has anticancer, anti-inflammatory, antioxidant and cardiovascular protective activities, it shows a novel inhibitory role on neuroinflammation, and presents a new candidate agent for the development of therapies for inflammation-related neurodegenerative diseases. Paeonol suppresses lipopolysaccharide-induced inflammatory cytokines in macrophage cells and protects mice from lethal endotoxin shock. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively; it inhibits PGE₂ synthesis and COX-2 expression, and modulates Sirtuin 1, PKCδ and c-Src signaling pathway.
Costunolide
Catalog No: CFN98928
Costunolide has antipyretic, anti-inflammatory, anti-oxidant, anti-carcinogenic and anti-fungal activities, it possesses normo-glycemic and hypolipidemic activity. Costunolide inhibits RANKL-induced osteoclast differentiation by suppressing RANKL-mediated c-Fos transcriptional activity; it inhibits IL-1beta gene expression by blocking the activation of MAPKs and DNA binding of AP-1; it also induces the ROS-mediated mitochondrial permeability transition and resultant cytochrome c release,
Mollugin
Catalog No: CFN98930
Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Mollugin has anticancer efficacy, can modulate the HER2, HO-1, Nrf2 , and NF- κB pathways.